Gene: SCYGR1
Official Full Name: small cysteine and glycine repeat containing 1provided by HGNC
Gene Summary: Predicted to be located in intermediate filament. [provided by Alliance of Genome Resources, Apr 2025]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO14298 | SCYGR1 Knockout cell line (HeLa) | Human | SCYGR1 | 1:3~1:6 | Negative | Online Inquiry |
KO14299 | SCYGR1 Knockout cell line (HCT 116) | Human | SCYGR1 | 1:2~1:4 | Negative | Online Inquiry |
KO14300 | SCYGR1 Knockout cell line (A549) | Human | SCYGR1 | 1:3~1:4 | Negative | Online Inquiry |
SCYGR1 Gene Knockout Cell Lines represent a cutting-edge tool in genetic research and therapeutic development. These cell lines have been engineered using CRISPR-Cas9 technology to disrupt the SCYGR1 gene, allowing for the in-depth study of its biological functions and implications in various diseases, particularly those involving immune responses and cell signaling pathways.
The key mechanism behind the functionality of SCYGR1 Gene Knockout Cell Lines is the precise alteration of the SCYGR1 gene, leading to a complete loss of protein expression. This knockout allows researchers to investigate the role of SCYGR1 in cellular processes such as proliferation, differentiation, and apoptosis, providing insights that can pave the way for potential therapeutic interventions. The absence of the SCYGR1 protein enables comparative studies between knockout and wild-type cells, facilitating a clearer understanding of its contributions to pathological processes.
From a scientific standpoint, the availability of SCYGR1 Gene Knockout Cell Lines is vital for basic research and drug development. These cell lines can serve as invaluable models for studying diseases where SCYGR1 expression is altered, such as certain cancers and autoimmune conditions. In clinical settings, these models can help in screening potential drugs targeting the SCYGR1 pathway, accelerating the translation of research findings into therapeutic applications.
Compared to traditional methods for gene disruption, such as homologous recombination, CRISPR-Cas9 provides a more efficient and specific means of creating knockout models. Researchers benefit from the ease of use and rapid development timeline associated with SCYGR1 Gene Knockout Cell Lines, allowing for high-throughput studies and reduced resource expenditure.
For researchers and clinicians seeking to uncover the functional significance of the SCYGR1 gene, our SCYGR1 Gene Knockout Cell Lines offer unparalleled value. They provide an innovative solution to explore gene function and therapeutic avenues, positioning your research at the forefront of genetic and biomedical advancements.
With extensive expertise in producing specialized biological products, our company is committed to delivering high-quality tools that empower the scientific community in their quest for discovery and innovation.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.